Genetic Variability in Beta-Defensins Is Not Associated with Susceptibility to Staphylococcus aureus Bacteremia by Fode, Peder et al.
Genetic Variability in Beta-Defensins Is Not Associated
with Susceptibility to Staphylococcus aureus Bacteremia
Peder Fode
1, Anders Rhod Larsen
1, Bjarke Feenstra
2, Cathrine Jespersgaard
3, Robert Leo Skov
1,
Marc Stegger
1, Vance G. Fowler Jr.
4, the Danish SAB Study Group Consortium
", Paal Skytt Andersen
1*
1Department for Microbiological Surveillance and Research, Statens Serum Institut, Copenhagen, Denmark, 2Department of Epidemiological Research, Statens Serum
Institut, Copenhagen, Denmark, 3Department of Clinical Biochemistry and Immunology, Statens Serum Institut, Copenhagen, Denmark, 4Department of Infectious
Diseases, Duke Medical Center, Durham, North Carolina, United States of America
Abstract
Introduction: Human beta-defensins are key components of human innate immunity to a variety of pathogens, including
Staphylococcus aureus. The aim of the present study was to investigate a potential association between gene variations in
DEFB1 and DEFB103/DEFB4 and the development of S. aureus bacteremia (SAB) employing a case-control design.
Methods: Cases were unique patients with documented SAB, identified with the National S. aureus Bacteremia Register, a
comprehensive dataset of all episodes of community associated-SABs (CA-SAB) occurring in children (#20 yrs) in Denmark
from 1990 to 2006. Controls were age-matched healthy individuals with no history of SAB. DNA obtained from cases and
controls using the Danish Newborn Screening Biobank were genotyped for functional polymorphisms of DEFB1 by Sanger
sequencing and copy number variation of the DEFB103 and DEFB4 genes using Pyrosequencing-based Paralogue Ratio Test
(P-PRT).
Results: 193 ethnic Danish SAB cases with 382 age-matched controls were used for this study. S. aureus isolates represented
a variety of bacterial (i.e., different spa types) types similar to SAB isolates in general. DEFB1 minor allele frequencies of
rs11362 (cases vs. controls 0.47/0.44), rs1800972 (0.21/0.24), and rs1799946 (0.32/0.33) were not significantly different in
cases compared with controls. Also, DEFB4/DEFB103 gene copy numbers (means 4.83/4.92) were not significantly different in
cases compared with controls.
Conclusions: Using a large, unique cohort of pediatric CA-SAB, we found no significant association between DEFB1 genetic
variation or DEFB4/DEFB103 gene copy number and susceptibility for SAB.
Citation: Fode P, Larsen AR, Feenstra B, Jespersgaard C, Skov RL, et al. (2012) Genetic Variability in Beta-Defensins Is Not Associated with Susceptibility to
Staphylococcus aureus Bacteremia. PLoS ONE 7(2): e32315. doi:10.1371/journal.pone.0032315
Editor: Michael Otto, National Institutes of Health, United States of America
Received September 8, 2011; Accepted January 26, 2012; Published February 22, 2012
Copyright:  2012 Fode et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work was supported by Danish Medical Research Council; Idella Foundation; and The Lundbeck Foundation. Dr. Fowler was supported by NIH
grant R01-AI068804. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: psa@ssi.dk
" Membership of the Danish SAB Study Group Consortium is provided in the Acknowledgments.
Introduction
Staphylococcus aureus is a leading cause of bacteremia and
endocarditis in the industrialized world. In 2008, the incidence
of S. aureus bacteremia (SAB) in Denmark was 25.6 cases per
100,000 inhabitants [1]. Approximately 20% of these cases had a
fatal outcome [1].
A growing body of evidence indicates that host genetic factors
are involved in susceptibility to a variety of bacterial pathogens,
including meningococci [2], Mycobacterium tuberculosis [3], and
leprosy [4,5]. Similar evidence also exists for genetic susceptibility
to S. aureus. For example, higher rates of invasive S. aureus infection
have been described in ethnically distinct populations, including
Australian Aborigines, New Zealand Maori, and Canadian Native
Americans [6]. Using a murine S. aureus sepsis model, Ahn et al.
recently demonstrated that inbred A/J mice were highly
susceptible to S. aureus infection as compared to C57BL6, and
that this susceptibility was associated with regions on A/J
chromosomes 8, 11, and 18, chromosomes that included defensin
genes and several other innate immune genes [7]. Additionally,
investigators at Erasmus University recently suggested that
variability within key innate immunity genes were associated with
persistent S. aureus carriage [8]. Despite these findings, however,
the precise genetic determinants for susceptibility to S. aureus
infection in humans are unknown.
Defensins are small cationic peptides with antimicrobial activity
[9–12] and shown to be important players in the innate immune
system. The majority of the defensin genes including DEFB1,
DEFB4 and DEFB103 encoding human beta-defensins 1, 2 and
23, respectively [13], are located on chromosome 8p23.1, a
region of great complexity with both functional SNPs (DEFB1) and
copy number variation (CNV) of a wide range of beta-defensin
genes including DEFB4 and DEFB103. DEFB1 is apparently
constitutively expressed [14], but functional single nucleotide
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susceptibility to severe sepsis [15]. Furthermore, human beta-
defensin 3 (HBD3) has a strong activity against S. aureus [16]. The
genomic copy number (GCN) for DEFB4/DEFB103 varies from 2
to 12 copies per diploid genome [13]. Interestingly, an increased
GCN of DEFB4/DEFB103 is associated with exacerbations of
psoriasis, an inflammatory skin disease characterized by a notable
absence of S. aureus colonization [17].
The combination of strong activity against S. aureus, functional
DEFB1 SNPs and high variability in DEFB4/DEFB103 GCN
makes these genes promising candidates for human susceptibility to
S. aureus infections. In the present study we used a unique cohort of
all pediatric patients with SAB in Denmark over a 16-year period to
evaluate potential associations between either functional SNPs of
DEFB1 or low GCN of DEFB4/DEFB103 and pediatric SAB.
Materials and Methods
Ethics Statement
The present study was approved by the Regional Science Ethics
Committee of Copenhagen (2007-0104), the Danish Data
Protection Agency (2008-54-0458), and The Danish Newborn
Screening Biobank’s review board a similar, but more independent
review board than an Institutional Review Board. The parents are
informed verbally and by homepage (www.ssi.dk/nyfoedte) about
the use of The Danish Newborn Screening Biobank and can opt
out at any time [18].
Identification of cases and controls
The present study included all Danish SAB pediatric patients in the
period 1990–2006. For the purposes of this study, pediatric patients
were defined as #20 years of age at the time of their SAB episode.
SAB acquisition was classified as Hospital associated (HA)-SAB,
Community associated (CA)-SAB or unknown, based on the time of
positive SAB sampling after hospital admission. A SAB episode was
registered as CA-SAB if diagnosed in less than 48 h after hospital
admission based on information retrieved prospectively from
discharge summaries. These data were retrieved from The Danish
S. aureus Bacteremia Database at SSI, containing all Danish SAB
isolates and corresponding bacteriological and patient data since 1958.
Patients were included if they were born after 1982, were of Danish
origin, and had CA-SAB. Danish origin was defined as individuals
where both of the individual’s parents were born in Denmark.
For each case two Danish individuals (same definition as for
cases) from The Danish Newborn Screening Biobank who
according to the Danish National Patient Registry had not been
diagnosed with SAB or other severe bacterial infections served as
controls. Samples for these control samples were adjacent to the
case samples in the biobank regardless of gender. Two controls
suffered from diabetes and two had died from cancer.
Bacteriological data
All S. aureus isolates were retrieved from The Danish S. aureus
Bacteremia Repository and were spa-typed according to standard
practise and assigned to clonal complexes (CC) [19].
DNA extraction
DNA was extracted from 3 mm filter paper blood samples using
Generation DNA Elution solution and DNA purification solution
(Qiagen, Valencia, CA) as described by Baker et al. [20]. Extraction
was performed in 96-well format with each well containing a dried
blood sample. Washing buffer (PBS, 0.5% Tween20) was added to
each well and the samples were shaken at 1000 rpm for 45 min at
room temperature before the supernatant was removed. The
washing procedure was repeated. Purification solution was added
and the supernatant was removed. The procedure was repeated. An
elution solution was then added and after 5 min the supernatant
was removed. Sterile water was added, and the plate was placed at
220uC for 15 min before being heated to 99uC for 15 min.
DEFB1 SNP analysis
Genotyping of three DEFB1 59UTR SNPs (rs11362 [220G/A];
rs1800972 [244 C/G] and rs1799946 [252 G/A]) was
performed using Sanger DNA sequencing after obtaining a
318 bp fragment (Forward primer: 59-CTC CCT TCA GTT
CCG T-39 and reverse primer 59-CTT GTT CCT CGT CCC
TT-39). Hardy-Weinberg equilibrium was seen in cases and
controls separately and combined for all three SNPs.
DEFB4/DEFB103 Copy number determination
Gene copy number was determined using the Pyrosequencing-
based Paralogue Ratio Test (P-PRT). The method is based on the
Paralogue Ratio Test (PRT) described previously [21,22]. In brief,
the DEFB103 region on chromosome 8 and an identified paralogue
gene (HSPD21 on chromosome 21) with only two copies per
genome were PCR amplified using one set of primers. The resulting
PCR amplicons differed at 10 positions. One of the positions where
the amplicons differed was used to quantify the two chromosome
regions against each other by pyrosequencing across it. The P-PRT
method used has recently been described [23].
Primers for the pyrosequencing assay were designed using the
PSQ assay design software version 1.0.6 (Qiagen, Hilden,
Germany). The following sequence was analysed with the position
that varied between chromosomes 8 and 21 marked in bold with
underline: KATGCYAT. For the PCR, 20 ng of template DNA in
a total volume of 50 ml using a forward primer (59-GAGGT-
CACTGTGATCAAAGAT-39) and a reverse primer (59-Biotin-
AACCTTCAGCACAGCTACTC-39) was used. Pyrosequencing
was carried out using 40 mL of the PCR product and a sequencing
primer (59-AGGTCACTGTGATCAAAGAT-39) on the PSQ 96
MA Pyrosequencer according to manufacturer’s recommendations
(Qiagen).
The relative percentages of the two variants were calculated by
the Pyrosequencing software (Qiagen) and used for the gene copy
number determination. Positive controls from Coriell Cell
Repositories with known copy number were included in each
run (NA07048: 4 copies; NA10846: 5 copies; NA10847: 7 copies
and NA10861 3 copies) and used to generate a correction curve by
linear regression. Corrected copy number estimates were calcu-
lated for each sample using this run-specific regression equation. A
‘‘No template control’’ was included in each run.
Statistical analysis
In the DEFB1 SNP analyses, we tested for association between
SNP genotype and case-control status using an additive genetic
model. We also tested for possible non-additive effects using
dominant, recessive, and full genotype models. Association tests
were performed using PLINK [24]. Mean gene copy numbers of
cases and controls were compared using unpaired t-test with the
Welch correction. If one of the groups did not have a Gaussian
distribution, a Mann–Whitney test was performed. Copy number
analyses were performed using R (http://www.r-project.org).
Power calculations
In the design phase of the study, we used published association
resultsbetweenhighercopynumberforb–defensingenesandriskof
psoriasis [25] to estimate power for various sample sizes. The effect
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mean copy number difference between cases and controls, and the
standard deviations of copy numbers in cases and controls ranged
between 1.1 and 1.3. Using an unpaired t-test with an significance
level of a=0.05 and assuming equal variances in cases and controls,
the power estimates based on these effect sizes ranged from 0.58
(true difference 0.25, standard deviation 1.3) to 0.98 (true difference
0.4, standard deviation 1.1) for 193 cases and 382 controls (see
Figure 1 for power curves). Using the largest observed standard
deviations in our study (1.17 in cases), the power was 0.67 for a true
effect size of 0.25, and for an effect size of 0.40 the power was 0.97.
Power calculations were performed using R.
Results
A total of 1,674 patients #20 years were diagnosed with SAB in
Denmark from 1990 to 2006. Of these patients, 464 had CA-SAB,
882 had HA-SAB, and for 328 patients the origin of infection
remained unknown. Among the CA-SAB pediatric cases, 193
patients met inclusion criteria being born after 1982 and had an
available blood sample in The Danish Newborn Screening
Biobank for DNA extraction. These 193 patients constitute the
cases for the present study.
Next, we identified control subjects. A total of two controls per
sample were selected for the study, but four had to be excluded
due to lack of DNA in the samples resulting in 382 controls. The
cases included 130 males (67%) and 63 females (33%). Among the
controls 229 (60%) were males and 153 (40%) were females. There
was no significant difference in gender distribution between cases
and controls (x
2=2.69, P=0.10). The gender distribution among
the included cases and controls was also similar to HA-SAB in
patients #20 years of age and to SAB patients in general.
Distribution of spa types and antibiogram
All isolates were susceptible to methicilin. The diversity of the
S. aureus isolates was determined by spa typing to elucidate if the
distribution was biased, e.g. whether specific types of S. aureus
were overrepresented in CA-SAB. We did, however, not find any
such bias as the distribution of phage groups were similar in both
the selected cases and other SAB patient cases both within the
same period and age group as well as among the total number of
cases retrieved from the SAB register (Table 1). A total of 113
different spa types were found among 192 isolates that were
assigned to 18 known CC groups. The remaining 31 isolates were
either missing (n=7) or had atypical spa repeats that could not be
assigned. The most prevalent CC groups were: CC45 (26.3%),
CC30 (20.4%), CC15 (12.9%), CC509 (6.5%), CC121 (6.5%),
and CC8 (4.8%).
DEFB1 SNP analysis
Patients and controls were genotyped for three DEFB1
promoter SNPs, rs11362 [220G/A]; rs1800972 [244 C/G]
and rs1799946 [252 G/A]. Results of the genotyping are given in
Table 2. The minor allele frequencies of the three SNPs did not
differ between SAB cases and controls (P.0.05 for all three SNPs).
Analyses with dominant, recessive and full genotype models as well
as haplotype analyses also did not show any differences between
cases and controls (data not shown).
DEFB4/DEFB103 Copy number determination
Gene copy number for DEFB4/DEFB103 v a r i e df r o m2t o9i n
both CA-SAB cases and controls with comparable frequency
distributions for the two groups (Figure 2). Mean copy numbers
(and standard deviations) for cases and controls were 4.83 (1.17)
and 4.92 (1.12). There was no significant difference in copy
number between cases and controls (P=0.33, t-test). However, a
Shapiro-Wilks test showed deviation from normality in the copy
number distribution for the controls (P=0.002). We therefore
also applied a Mann-Whitney test, but again we found no
significant difference in copy number between cases and controls
(P=0.37).
Figure 1. Power curves for an unpaired t-test with 193 cases and 382 controls, assuming equal variance in cases and controls and a
significance level of 0.05. True difference in mean copy number is shown on the x-axis, and the power to detect such differences is shown on the
y-axis. Curves are shown for three different copy number standard deviations: 1.1 (solid), 1.2 (dashed), and 1.3 (dotted).
doi:10.1371/journal.pone.0032315.g001
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Using a large, Caucasian Danish, and clinically well-described
bacteremia registry of children with CA-SAB, we found no
association between the DEFB1 SNPs (rs11362 [220G/A];
rs1800972 [244 C/G] and rs1799946 [252 G/A]) or the
DEFB4/DEFB103 GCN and susceptibility to CA-SAB [23]. The
CA-SAB isolates in our registry were of diverse types indicating
that no specific type was dominant among CA-SABs.
We have established a large well-characterized nested CA-SAB
case-control study (193 cases and 382 controls), which has allowed
us to study genetic association in an ethnic homogenous
population. This is among the largest CA-SAB cohorts for genetic
association studies, and our study had good statistical power to
detect case-control differences in mean copy number larger than
0.25. It is, however, possible that weaker genetic associations exist
that will not be detected with a cohort of this size. The GCN was
determined by P-PRT, which we previously have shown to be a
reliable method [23], but like other GCN assays is associated with
errors. However, in the present study the relative differences
between cases and controls rather than exact GCN are the
principal aim where we assume similar error rates in cases and
controls.
Defensin genes have been the focus of the present susceptibility
study as the functional consequences of such mutations appear to
be associated with reduced expression and presumably reduced
activity of the resulting peptides. A promoter polymorphism
(rs11362) of DEFB1 has previously been shown to be associated
with sepsis [15]. However, we did not see any association between
either the DEFB1 polymorphism or other closely positioned
polymorphisms and SAB in a study population comparable in size
(193 vs. 211) to that of Chen and co-workers [15]. The genetic
association previously found could thus be the result of infection by
other types of bacteria than SAB or the difference could be due to
ethnic differences between the two studies or the fact that our
study is focused only on S. aureus bacteremia cases in contrast to
the broader study of Chen and co-workers who did not distinguish
between different bacterial infections.
It is intriguing that we now have the possibility to address the
issue of genetic association to a specific type of bacterial infection.
Addressing other candidate genes based on information from
Table 1. Phage distribution among SAB cases 1990–2006.
Phage pattern Phage type CA-SAB pts.#20 yrs. Other SAB#20 yrs. All SAB
No. (%) No. (%) No. (%)
80 Complex 80, 81+combination of 52 and/or 52A with 80 and/or 81 3 (1.6) 27 (1.6) 1547 (6.4)
Rest of phage group I 29, 52, 52A, 79, 80 30 (15.5) 248 (14.8) 4396 (18.1)
Phage group II 3A, 3C, 55, 71 39 (20.2) 357 (21.4) 4256 (17.6)
Phage group III 6, 42E, 47, 53, 54, 75, 77, (81), 83A, 84, 85, 89, 93 23 (11.9) 201 (12.0) 3561 (14.7)
83A Complex Combination of one or more of only 83A, 84, 85, 89, 93 9 (4.7) 74 (4.4) 966 (4.0)
94,96 Complex 94, 96 3 (1.6) 73 (4.4) 1596 (6.6)
Type 95 95 25 (13.0) 317 (18.9) 3864 (16.0)
NI (mixed phage group) Mixture of the reactions in the phage type pattern above 28 (14.5) 155 (9.3) 1695 (7.0)
NT(non typable Non typable at phage concentration 10006Routine Test
Dilution (RTD)
33 (17.1) 222 (13.3) 2347 (9.7)
doi:10.1371/journal.pone.0032315.t001
Table 2. DEFB1 Genotype and minor allele frequencies in CA-
SAB cases and controls.
CA-SAB Controls P value
n (%) n (%)
[220G/A] (rs11362)
GG 60 (31) 123 (32)
GA 85 (44) 182 (48)
AA 48 (25) 76 (20)
Minor allele (A) 181(47) 334 (44) P=0.32
[244 C/G] (rs1800972)
CC 119 (62) 224 (59)
CG 68 (35) 133 (35)
GG 7 (4) 23 (6)
Minor allele (G) 82 (21) 179 (24) P=0.36
[252 G/A] (rs1799946)
GG 93 (48) 170 (45)
GA 78 (40) 171 (45)
AA 23 (12) 39 (10)
Minor allele (A) 124 (32) 249 (33) P=0.78
doi:10.1371/journal.pone.0032315.t002
Figure 2. Frequency distribution of DEFB4/DEFB103 GCN for
SAB cases and controls.
doi:10.1371/journal.pone.0032315.g002
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the genetic susceptibility to S. aureus bacteremia.
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